TY - JOUR AU - Podo, F. AU - Buydens, L. M. AU - Degani, H. AU - Hilhorst, R. AU - Klipp, E. AU - Gribbestad, I. S. PY - 2010 DA - 2010// TI - Triple-negative breast cancer: present challenges and new perspectives JO - Mol Oncol VL - 4 UR - https://doi.org/10.1016/j.molonc.2010.04.006 DO - 10.1016/j.molonc.2010.04.006 ID - Podo2010 ER - TY - JOUR AU - Dent, R. AU - Trudeau, M. AU - Pritchard, K. I. AU - Hanna, W. M. AU - Kahn, H. K. AU - Sawka, C. A. PY - 2007 DA - 2007// TI - Triple-negative breast cancer: clinical features and patterns of recurrence JO - Clin Cancer Res VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-06-3045 DO - 10.1158/1078-0432.CCR-06-3045 ID - Dent2007 ER - TY - JOUR AU - Liedtke, C. AU - Mazouni, C. AU - Hess, K. R. AU - Andre, F. AU - Tordai, A. AU - Mejia, J. A. PY - 2008 DA - 2008// TI - Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.14.4147 DO - 10.1200/JCO.2007.14.4147 ID - Liedtke2008 ER - TY - JOUR AU - Kumar, P. AU - Aggarwal, R. PY - 2016 DA - 2016// TI - An overview of triple-negative breast cancer JO - Arch Gynecol Obstet VL - 293 UR - https://doi.org/10.1007/s00404-015-3859-y DO - 10.1007/s00404-015-3859-y ID - Kumar2016 ER - TY - JOUR AU - Stagg, J. AU - Allard, B. PY - 2013 DA - 2013// TI - Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects JO - Ther Adv Med Oncol VL - 5 UR - https://doi.org/10.1177/1758834012475152 DO - 10.1177/1758834012475152 ID - Stagg2013 ER - TY - JOUR AU - van Rooijen, J. M. AU - Stutvoet, T. S. AU - Schroder, C. P. AU - de Vries, E. G. PY - 2015 DA - 2015// TI - Immunotherapeutic options on the horizon in breast cancer treatment JO - Pharmacol Ther VL - 156 UR - https://doi.org/10.1016/j.pharmthera.2015.09.003 DO - 10.1016/j.pharmthera.2015.09.003 ID - van Rooijen2015 ER - TY - JOUR AU - Fisher, C. S. AU - Ma, C. X. AU - Gillanders, W. E. AU - Aft, R. L. AU - Eberlein, T. J. AU - Gao, F. PY - 2012 DA - 2012// TI - Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response JO - Ann Surg Oncol VL - 19 UR - https://doi.org/10.1245/s10434-011-1877-y DO - 10.1245/s10434-011-1877-y ID - Fisher2012 ER - TY - JOUR AU - Kong, X. AU - Moran, M. S. AU - Zhang, N. AU - Haffty, B. AU - Yang, Q. PY - 2011 DA - 2011// TI - Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients JO - Eur J Cancer VL - 47 UR - https://doi.org/10.1016/j.ejca.2011.06.014 DO - 10.1016/j.ejca.2011.06.014 ID - Kong2011 ER - TY - JOUR AU - Denkert, C. AU - Loibl, S. AU - Noske, A. AU - Roller, M. AU - Muller, B. M. AU - Komor, M. PY - 2010 DA - 2010// TI - Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.23.7370 DO - 10.1200/JCO.2009.23.7370 ID - Denkert2010 ER - TY - JOUR AU - Jung, Y. Y. AU - Hyun, C. L. AU - Jin, M. S. AU - Park, I. A. AU - Chung, Y. R. AU - Shim, B. PY - 2016 DA - 2016// TI - Histomorphological factors predicting the response to neoadjuvant chemotherapy in triple-negative breast Cancer JO - J Breast Cancer VL - 19 UR - https://doi.org/10.4048/jbc.2016.19.3.261 DO - 10.4048/jbc.2016.19.3.261 ID - Jung2016 ER - TY - JOUR AU - Garcia-Martinez, E. AU - Gil, G. L. AU - Benito, A. C. AU - Gonzalez-Billalabeitia, E. AU - Conesa, M. A. AU - Garcia Garcia, T. PY - 2014 DA - 2014// TI - Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer JO - Breast Cancer Res VL - 16 UR - https://doi.org/10.1186/s13058-014-0488-5 DO - 10.1186/s13058-014-0488-5 ID - Garcia-Martinez2014 ER - TY - JOUR AU - Castaneda, C. A. AU - Mittendorf, E. AU - Casavilca, S. AU - Wu, Y. AU - Castillo, M. AU - Arboleda, P. PY - 2016 DA - 2016// TI - Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy JO - World J Clin Oncol VL - 7 UR - https://doi.org/10.5306/wjco.v7.i5.387 DO - 10.5306/wjco.v7.i5.387 ID - Castaneda2016 ER - TY - JOUR AU - Loi, S. AU - Sirtaine, N. AU - Piette, F. AU - Salgado, R. AU - Viale, G. AU - Van Eenoo, F. PY - 2013 DA - 2013// TI - Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98 JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2011.41.0902 DO - 10.1200/JCO.2011.41.0902 ID - Loi2013 ER - TY - JOUR AU - Salgado, R. AU - Denkert, C. AU - Demaria, S. AU - Sirtaine, N. AU - Klauschen, F. AU - Pruneri, G. PY - 2015 DA - 2015// TI - The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014 JO - Ann Oncol VL - 26 UR - https://doi.org/10.1093/annonc/mdu450 DO - 10.1093/annonc/mdu450 ID - Salgado2015 ER - TY - JOUR AU - Wolff, A. C. AU - Hammond, M. E. AU - Schwartz, J. N. AU - Hagerty, K. L. AU - Allred, D. C. AU - Cote, R. J. PY - 2007 DA - 2007// TI - American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.09.2775 DO - 10.1200/JCO.2006.09.2775 ID - Wolff2007 ER - TY - JOUR AU - Hammond, M. E. AU - Hayes, D. F. AU - Wolff, A. C. AU - Mangu, P. B. AU - Temin, S. PY - 2010 DA - 2010// TI - American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer JO - J Oncol Pract VL - 6 UR - https://doi.org/10.1200/JOP.777003 DO - 10.1200/JOP.777003 ID - Hammond2010 ER - TY - STD TI - Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO Classification of Tumours of the Breast. Lyon: IARC. 2012;4. ID - ref17 ER - TY - JOUR AU - Bloom, H. J. AU - Richardson, W. W. PY - 1957 DA - 1957// TI - Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years JO - Br J Cancer VL - 11 UR - https://doi.org/10.1038/bjc.1957.43 DO - 10.1038/bjc.1957.43 ID - Bloom1957 ER - TY - JOUR AU - Elston, C. W. AU - Ellis, I. O. PY - 1991 DA - 1991// TI - Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up JO - Histopathology VL - 19 UR - https://doi.org/10.1111/j.1365-2559.1991.tb00229.x DO - 10.1111/j.1365-2559.1991.tb00229.x ID - Elston1991 ER - TY - JOUR AU - Ogston, K. N. AU - Miller, I. D. AU - Payne, S. AU - Hutcheon, A. W. AU - Sarkar, T. K. AU - Smith, I. PY - 2003 DA - 2003// TI - A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival JO - Breast (Edinburgh, Scotland) VL - 12 UR - https://doi.org/10.1016/S0960-9776(03)00106-1 DO - 10.1016/S0960-9776(03)00106-1 ID - Ogston2003 ER - TY - JOUR AU - Ono, M. AU - Tsuda, H. AU - Shimizu, C. AU - Yamamoto, S. AU - Shibata, T. AU - Yamamoto, H. PY - 2012 DA - 2012// TI - Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer JO - Breast Cancer Res Treat VL - 132 UR - https://doi.org/10.1007/s10549-011-1554-7 DO - 10.1007/s10549-011-1554-7 ID - Ono2012 ER - TY - JOUR AU - Denkert, C. AU - Loibl, S. AU - Salat, C. AU - Sinn, B. AU - Schem, C. AU - Endris, V. PY - 2013 DA - 2013// TI - Abstract S1–06: Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66) JO - Cancer Res VL - 73 UR - https://doi.org/10.1158/0008-5472.SABCS13-S1-06 DO - 10.1158/0008-5472.SABCS13-S1-06 ID - Denkert2013 ER - TY - JOUR AU - Loi, S. AU - Michiels, S. AU - Salgado, R. AU - Sirtaine, N. AU - Jose, V. AU - Fumagalli, D. PY - 2014 DA - 2014// TI - Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial JO - Ann Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdu112 DO - 10.1093/annonc/mdu112 ID - Loi2014 ER - TY - JOUR AU - Adams, S. AU - Gray, R. J. AU - Demaria, S. AU - Goldstein, L. AU - Perez, E. A. AU - Shulman, L. N. PY - 2014 DA - 2014// TI - Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199 JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.55.0491 DO - 10.1200/JCO.2013.55.0491 ID - Adams2014 ER - TY - JOUR AU - Pruneri, G. AU - Vingiani, A. AU - Bagnardi, V. AU - Rotmensz, N. AU - De Rose, A. AU - Palazzo, A. PY - 2016 DA - 2016// TI - Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdv571 DO - 10.1093/annonc/mdv571 ID - Pruneri2016 ER - TY - JOUR AU - Park, H. S. AU - Heo, I. AU - Kim, J. Y. AU - Kim, S. AU - Nam, S. AU - Park, S. PY - 2016 DA - 2016// TI - No effect of tumor-infiltrating lymphocytes (TILs) on prognosis in patients with early triple-negative breast cancer: validation of recommendations by the international TILs working group 2014 JO - J Surg Oncol VL - 114 UR - https://doi.org/10.1002/jso.24275 DO - 10.1002/jso.24275 ID - Park2016 ER - TY - JOUR AU - Tian, T. AU - Ruan, M. AU - Yang, W. AU - Shui, R. PY - 2016 DA - 2016// TI - Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers JO - Oncotarget VL - 7 ID - Tian2016 ER - TY - JOUR AU - Swisher, S. K. AU - Wu, Y. AU - Castaneda, C. A. AU - Lyons, G. R. AU - Yang, F. AU - Tapia, C. PY - 2016 DA - 2016// TI - Interobserver agreement between pathologists assessing tumor-infiltrating lymphocytes (TILs) in breast Cancer using methodology proposed by the international TILs working group JO - Ann Surg Oncol VL - 23 UR - https://doi.org/10.1245/s10434-016-5173-8 DO - 10.1245/s10434-016-5173-8 ID - Swisher2016 ER - TY - JOUR AU - Mao, Y. AU - Qu, Q. AU - Zhang, Y. AU - Liu, J. AU - Chen, X. AU - Shen, K. PY - 2014 DA - 2014// TI - The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis JO - PLoS One VL - 9 UR - https://doi.org/10.1371/journal.pone.0115103 DO - 10.1371/journal.pone.0115103 ID - Mao2014 ER - TY - JOUR AU - Wang, K. AU - Xu, J. AU - Zhang, T. AU - Xue, D. PY - 2016 DA - 2016// TI - Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: a meta-analysis JO - Oncotarget VL - 7 ID - Wang2016 ER - TY - JOUR AU - Li, X. B. AU - Krishnamurti, U. AU - Bhattarai, S. AU - Klimov, S. AU - Reid, M. D. AU - O'Regan, R. PY - 2016 DA - 2016// TI - Biomarkers predicting pathologic complete response to neoadjuvant chemotherapy in breast Cancer JO - Am J Clin Pathol VL - 145 UR - https://doi.org/10.1093/ajcp/aqw045 DO - 10.1093/ajcp/aqw045 ID - Li2016 ER - TY - JOUR AU - Hida, A. I. AU - Sagara, Y. AU - Yotsumoto, D. AU - Kanemitsu, S. AU - Kawano, J. AU - Baba, S. PY - 2016 DA - 2016// TI - Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between triple-negative and HER2-positive breast cancers treated with standard systemic therapies JO - Breast Cancer Res Treat VL - 158 UR - https://doi.org/10.1007/s10549-016-3848-2 DO - 10.1007/s10549-016-3848-2 ID - Hida2016 ER - TY - STD TI - Khoury T, Nagrale V, Opyrchal M, Peng X, Wang D, Yao S. Prognostic significance of stromal versus Intratumoral infiltrating lymphocytes in different subtypes of breast Cancer treated with cytotoxic neoadjuvant chemotherapy: Applied immunohistochemistry & molecular morphology : AIMM; 2017:1. ID - ref33 ER - TY - JOUR AU - Issa-Nummer, Y. AU - Darb-Esfahani, S. AU - Loibl, S. AU - Kunz, G. AU - Nekljudova, V. AU - Schrader, I. PY - 2013 DA - 2013// TI - Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial JO - PLoS One VL - 8 UR - https://doi.org/10.1371/journal.pone.0079775 DO - 10.1371/journal.pone.0079775 ID - Issa-Nummer2013 ER - TY - JOUR AU - Denkert, C. AU - von Minckwitz, G. AU - Brase, J. C. AU - Sinn, B. V. AU - Gade, S. AU - Kronenwett, R. PY - 2015 DA - 2015// TI - Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.58.1967 DO - 10.1200/JCO.2014.58.1967 ID - Denkert2015 ER - TY - JOUR AU - Ingold Heppner, B. AU - Untch, M. AU - Denkert, C. AU - Pfitzner, B. M. AU - Lederer, B. AU - Schmitt, W. PY - 2016 DA - 2016// TI - Tumor-infiltrating lymphocytes: a predictive and prognostic biomarker in neoadjuvant-treated HER2-positive breast Cancer JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-2338 DO - 10.1158/1078-0432.CCR-15-2338 ID - Ingold Heppner2016 ER - TY - JOUR AU - Krishnamurti, U. AU - Wetherilt, C. S. AU - Yang, J. AU - Peng, L. AU - Li, X. PY - 2017 DA - 2017// TI - Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers JO - Hum Pathol VL - 64 UR - https://doi.org/10.1016/j.humpath.2017.01.004 DO - 10.1016/j.humpath.2017.01.004 ID - Krishnamurti2017 ER - TY - JOUR AU - Chung, Y. R. AU - Kim, H. J. AU - Jang, M. H. AU - Park, S. Y. PY - 2017 DA - 2017// TI - Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status JO - Breast Cancer Res Treat VL - 161 UR - https://doi.org/10.1007/s10549-016-4072-9 DO - 10.1007/s10549-016-4072-9 ID - Chung2017 ER - TY - JOUR AU - Pan, B. J. AU - Ping, G. Q. AU - Zhang, W. M. AU - Wang, C. AU - Li, H. X. AU - Zhang, Z. H. PY - 2016 DA - 2016// TI - CD8 and FOXP3 expression in stromal tumor-infiltrating lymphocytes of triple-negative breast carcinomas: a clinicopathologic study JO - Zhonghua bing li xue za zhi VL - 45 ID - Pan2016 ER - TY - JOUR AU - Lee, H. J. AU - Park, I. A. AU - Song, I. H. AU - Shin, S. J. AU - Kim, J. Y. AU - Yu, J. H. PY - 2016 DA - 2016// TI - Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer JO - J Clin Pathol VL - 69 UR - https://doi.org/10.1136/jclinpath-2015-203089 DO - 10.1136/jclinpath-2015-203089 ID - Lee2016 ER - TY - JOUR AU - Seo, A. N. AU - Lee, H. J. AU - Kim, E. J. AU - Kim, H. J. AU - Jang, M. H. AU - Lee, H. E. PY - 2013 DA - 2013// TI - Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer JO - Br J Cancer VL - 109 UR - https://doi.org/10.1038/bjc.2013.634 DO - 10.1038/bjc.2013.634 ID - Seo2013 ER - TY - JOUR AU - Asano, Y. AU - Kashiwagi, S. AU - Goto, W. AU - Kurata, K. AU - Noda, S. AU - Takashima, T. PY - 2016 DA - 2016// TI - Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer JO - Br J Surg VL - 103 UR - https://doi.org/10.1002/bjs.10127 DO - 10.1002/bjs.10127 ID - Asano2016 ER -